Work

Mutant‐Selective Allosteric EGFR Degraders are Effective Against a Broad Range of Drug‐Resistant Mutations

Year: 2020

Type: article

Source: Angewandte Chemie

DOI: 10.1002/ange.202003500

Authors: Jaebong Jang, Ciric To, Dries J. H. De Clercq, Eunyoung Park, Charles M. Ponthier, Bo Hee Shin, Mierzhati Mushajiang, Radosław P. Nowak, Eric S. Fischer, Michael J. Eck, Pasi A. Jänne, Nathanael S. Gray

Institutions: Harvard University, Korea University, Dana-Farber Cancer Institute, Dana-Farber/Harvard Cancer Center

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funders: National Institutes of Health, National Cancer Institute

Awards: Protein Kinase Therapeutic Targets for Non-Small Cell Lung Carcinoma, G7768958537, G9000260971

OpenAlex ID: W4213237202

FWCI: 1.475

Cites: 44

Cited by: 16

Related to: 10